Is BB Biotech AG a good investment? BB Biotech AG (BBZA.DE) is currently trading at 58.50 EUR.
Earnings Schedule: BB Biotech AG is expected to release its next earnings report on Oct. 23, 2026. The market consensus estimate for Forward EPS is 2.17.
For income investors, BB Biotech AG pays a dividend yield of 4.00%. With a payout ratio of 9%, the dividend appears sustainable.
Yes, it pays an annual dividend of 2.25 EUR (4.00% yield).
BB Biotech AG is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be Oct. 23, 2026. The company currently has a trailing EPS of -8.60.
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
| Year | Total Dividends |
|---|---|
| ▸2027 |
2.19 EUR
|
| March 29, 2027 (estimated) | 2.1879 |
| ▸2026 |
4.84 EUR
|
| March 25, 2026 | 2.4311 |
| March 23, 2026 | 2.4075 |
| ▸2025 |
1.60 EUR
|
| March 21, 2025 | 1.6038 |
| ▸2024 |
4.20 EUR
|
| March 27, 2024 | 2.0593 |
| March 25, 2024 | 2.1400 |
| ▸2023 |
5.90 EUR
|
| March 29, 2023 | 2.8500 |
| March 27, 2023 | 3.0495 |
| ▸2022 |
7.97 EUR
|
| March 23, 2022 | 3.8500 |
| March 21, 2022 | 4.1195 |
| ▸2021 |
7.45 EUR
|
| March 24, 2021 | 3.6000 |
| March 22, 2021 | 3.8520 |
| ▸2020 |
3.40 EUR
|
| March 25, 2020 | 3.4000 |
| ▸2019 |
3.05 EUR
|
| March 27, 2019 | 3.0500 |
| ▸2018 |
3.30 EUR
|
| March 19, 2018 | 3.3000 |
| ▸2017 |
2.75 EUR
|
| March 22, 2017 | 2.7500 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| BB Biotech AG | Mar 23, 2026 | Paid | 2.4075 EUR |
| BB Biotech AG | Mar 25, 2026 | Paid | 2.43113 EUR |
| Split Date | Split Ratio to 1 |
|---|---|
| March 29, 2016 | 5:1 |
Community Discussion